In the population of heavily pretreated metastatic castration-resistant prostate cancer pts ADXS-PSA + pembro showed promising activity compared to monotherapy.
The combination of Nivolumab and ramucirumab showed promising antitumor activity in previously treated advanced gastric cancer.
Durvalumab showed a tolerable safety profile and evidence of antitumor activity in this mostly second line+ cohort of gastroesophageal (GE) cancer patients.
The results of this trial confirm that Pembrolizumab (pembro) may be a promising treatment option for patients with advanced hepatocellular carcinoma (HCC).
The findings from this study indicate that pamrevlumab may be a valuable addition to neoadjuvant therapy in locally advanced pancreatic cancer (LAPC) without added toxicity.
BBI608 with pembrolizumab showed preliminary efficacy signals in pts with Microsatellite Instability–High (MSI-H) mCRC as well as Non-MSI-H mCRC pts with right-sided primary.
The first phase II study of panitumumab combined with TAS-102 in patients with RAS wt metastatic colorectal cancer (mCRC) showed favorable antitumor activity for pretreated pts.
The TAILOR study confirmed cetuximab (cet) in combination with FOLFOX-4 as an effective standard-of-care of first-line (1L) treatment regimen for pts with RAS wt mCRC.
Pembrolizumab provided durable antitumor activity in patients with advanced microsatellite instability high (MSI-H) colorectal cancer that progressed after ≥1 prior line of thera...
A significantly higher objective response rate (ORR) was demonstrated for FOLFIRI plus cetuximab compared to FOLFIRI plus bevacizumab in this trial by Stintzing S. et al.
mFOLFOXIRI plus panitumumab as first-line treatment in patients with RAS wild- type metastatic colorectal cancer m(CRC) results in significantly higher response rates compared to ...
Randomized phase II study of regorafenib followed by cetuximab showed longer OS versus the reverse sequence for pretreated mCRC pts regardless of biomarker subgroups.
The authors of the trial identified that RAS and EGFR MT alleles decay exponentially over time since last EGFRi.
In a trial by Lisberg AE et al., pembrolizumab lacked efficacy in TKI naive, PD-L1+, EGFR-mutant patients with NSCLC.
Nivo demonstrated sustained efficacy benefit vs Ipi in pts with resected stage III/IV melanoma at high risk of recurrence, regardless of disease stage, PD-L1 expression, or BRAF mu...
The combination of epacadostat + nivolumab continues to show promising antitumor activity in pts with advanced melanoma and is generally well tolerated.
BMS-986205 + nivolumab was well tolerated, with a safety profile similar to that of nivolumab monotherapy.
Pembrolizumab monotherapy demonstrated promising efficacy and acceptable tolerability in patients with advanced clear cell renal cell carcinoma.
The combination of nivolumab to concurrent chemo-RT in stage III NSCLC appears to be safe and tolerable, according to the early interim safety analysis of the ETOP NICOAS trial
Pegilodecakin with nivolumab or pembrolizumab is well-tolerated in patients with metastatic renal cell carcinoma. The efficacy and the observed CD8+ T cell activation are very enco...
Neoadjuvant treatment with nivolumab +/- ipilimumab can produce pathologic complete response in high-risk resectable metastatic melanoma.
The combination of first-line nivolumab + chemotherapy in patients with advanced NSCLC and <1% PD-L1 expression improved PFS vs. chemo alone, and was well tolerated.
IMMER MEHR BEREICHE des täglichen Lebens werden per Mausklick geregelt: Die Digitalisierung ist dabei, in alle Ritzen unseres Lebens einzudringen.
ICH BEMERKE BEI meinen Klientengesprächen, dass viele OrdinationsinhaberInnen der Frage der Team-Zusammensetzung wenig Augenmerk schenken.
Authentische, teils geradezu spektakuläre Bilder sind Teil der DNA der Medical Tribune. Von Beginn an sorgten gerade auch die medizinischen Fotos in der MT für Gesprächsstoff...
Mit einer Anmeldung bei MEDONLINE haben Sie Zugriff auf Fortbildungen, Arzneimittelinfos, Produktfortbildungen und mehr. Registrieren Sie sich kostenlos auf MEDONLINE. Registrieren
...so that we can improve our services for you. Your data will be evaluated anonymously.